Analyst projections for bluebird bio (NASDAQ: BLUE) are varied, with a range of viewpoints from bullish to bearish. In the last quarter, 6 analysts provided ratings, with 2 bullish, 1 somewhat bullish, 2 indifferent, and 1 somewhat bearish, showing a mix of sentiments. The average 12-month price target for bluebird bio is $6.17, with a high estimate of $12.00 and a low estimate of $1.02, indicating a potential decline from the previous average price target.
Recent actions by analysts include lowering or raising their ratings and price targets for bluebird bio. For example, Morten Herholdt from HSBC downgraded the rating to Reduce with a price target of $1.02, while Jason Gerberry from B of A Securities both downgraded and upgraded the rating to Buy with price targets of $5.00 and $12.00 respectively. Yanan Zhu from Wells Fargo downgraded the rating to Equal-Weight with a price target of $5.00, Jack Allen from Baird downgraded the rating to Outperform with a price target of $7.00, and Jeffrey Hung from Morgan Stanley upgraded the rating to Equal-Weight with a price target of $7.00.
These recent actions by analysts reflect their responses to market dynamics and company performance, offering insights into their perspectives on the future prospects of bluebird bio.
Bluebird Bio Inc. (BLUE) Stock Faces Decline: What Investors Need to Know
On March 5, 2024, Bluebird Bio Inc. (BLUE) experienced a decline in its stock performance. According to data from CNN Money, BLUE is currently trading near the bottom of its 52-week range and below its 200-day simple moving average. This indicates that the stock may be facing some downward pressure in the market.
The price of BLUE shares dropped by $0.03 since the market last closed, representing a 2.24% decrease. In pre-market trading, the stock has continued to decline, dropping an additional $0.02.
This recent decline in BLUE’s stock price may be concerning for investors, as it suggests that there may be some negative sentiment surrounding the company. It is important for investors to closely monitor the stock’s performance and any news or developments that may be impacting its price.
Investors should conduct thorough research and analysis before making any investment decisions. Understanding the factors influencing a stock’s performance can help investors make more informed choices. As BLUE continues to trade near the bottom of its 52-week range, investors should proceed with caution and consider seeking advice from financial professionals.
BLUE Stock Analysis: Revenue Growth and Improved Net Income Signal Promising Future
On March 5, 2024, BLUE stock had an interesting performance based on the financial data provided by CNN Money. The company’s total revenue stood at $3.60 million for the past year, which remained flat compared to the previous year. However, the total revenue saw a significant increase of 79.85% since the last quarter, reaching $12.39 million. In terms of net income, BLUE reported a net loss of $266.58 million for the past year, which was an improvement of 67.47% compared to the previous year. Despite the net losses, the company seems to be making progress in reducing its losses over time. Earnings per share (EPS) also showed positive trends for BLUE stock. The EPS was reported at -$3.39 for the past year, representing a 71.47% increase compared to the previous year. Overall, the financial performance of BLUE stock on March 5, 2024, seems to be promising with significant revenue growth and improvements in net income and EPS. Investors may view these positive trends as a sign of potential growth and profitability for the company in the future.
